J&J, states settle on Risperdal

As part of a $181-million settlement with states to resolve charges of improper marketing and advertising, Johnson & Johnson agreed to stop several practices regarding Ripserdal and its cousin Invega.

These include misusing CME programs for marketing; awarding grants to doctors based on prescribing habits; presenting information that is not scientifically sound; and disseminating reprints with off-label usage information.

At press time, J&J was expected to pay up to $2.2 billion for the same allegations by DOJ involving these and other drugs.

On its website, J&J said it's not admititng any Risperdal wrongdoing.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


As US pharma continued its quest for a Grand Prix at the Lions Health international festival of creativity, MM&M went on location to Cannes, France. Missed our coverage from June? Now, we're giving you an opportunity to catch up on some of what you missed. Download our e-book on the two-day festival, recapping the event, rounding up the best of the speakers, offering perspective and listing all of the winners. Click here to download.


The most recent MM&M Skill Sets Live event surveyed a range of issues relating to one of the hottest promotional spaces in healthcare. Speakers and panelists at the morning-long session, including promotional- and multichannel-minded executives from GSK, Epocrates, Treato and Montefiore Medical Center, weighed in on topics designed to help marketers demystify the challenges associated with non-personal promotion. Click here.